In the Clinic Chagas Disease

被引:23
作者
Hochberg, Natasha S. [1 ,2 ,3 ]
Montgomery, Susan P. [4 ]
机构
[1] Boston Univ, Sch Med, Boston, MA 02215 USA
[2] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA
[3] Boston Med Ctr, Boston, MA 02118 USA
[4] CDCP, Parasit Dis Branch, Atlanta, GA, Georgia
关键词
TRYPANOSOMA-CRUZI INFECTION; RANDOMIZED-TRIAL; UNITED-STATES; TRANSMISSION; BENZNIDAZOLE; RECOMMENDATIONS; TRANSPLANTATION; MANAGEMENT; CONSENSUS; SOCIETY;
D O I
10.7326/AITC202302210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chagas disease, which is caused by infection with the parasite Trypanosoma cruzi, is a leading neglected tropical disease in the United States. An estimated 240 000 to 350 000 persons in the United States are infected, primarily immigrants from Mexico, Central America, and South America, where the disease is endemic. The parasite is transmitted by the triatomine bug but can also be passed through blood transfusion, via organ transplant, or congenitally. Approximately 30% of infected persons later develop cardiac and/or gastrointestinal complications. Health care providers should consider screening at-risk patients with serologic testing. Early diagnosis and treatment with benznidazole or nifurtimox can help prevent complications.
引用
收藏
页码:17 / 32
页数:16
相关论文
共 50 条
  • [21] Chagas Disease: Chronic Chagas Cardiomyopathy
    Echavarria, Natalia Giraldo
    Echeverria, Luis E.
    Stewart, Merrill
    Gallego, Catalina
    Saldarriaga, Clara
    CURRENT PROBLEMS IN CARDIOLOGY, 2021, 46 (03)
  • [22] Chagas disease
    Develoux, M.
    Lescure, F. -X.
    Le Loup, G.
    Pialoux, G.
    REVUE DE MEDECINE INTERNE, 2009, 30 (08): : 686 - 695
  • [23] Old and new challenges in Chagas disease
    Perez-Molina, Jose A.
    Martinez Perez, Angela
    Norman, Francesca F.
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    LANCET INFECTIOUS DISEASES, 2015, 15 (11) : 1347 - 1356
  • [24] Drug discovery for chagas disease: A viewpoint
    Kratz, Jadel Muller
    ACTA TROPICA, 2019, 198
  • [25] Novel drug discovery for Chagas disease
    Moraes, Carolina B.
    Franco, Caio H.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (05) : 447 - 455
  • [26] An evaluation of nifurtimox for Chagas disease in children
    Lascano, Fernanda
    Altcheh, Jaime
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (05): : 139 - 149
  • [27] Immunosuppression and Chagas disease; experience from a non-endemic country
    Salvador, F.
    Sanchez-Montalva, A.
    Valerio, L.
    Serre, N.
    Roure, S.
    Trevino, B.
    Pou, D.
    Sulleiro, E.
    Bocanegra, C.
    Molina, I.
    CLINICAL MICROBIOLOGY AND INFECTION, 2015, 21 (09) : 854 - 860
  • [28] Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States
    Irish, Amanda
    Whitman, Jeffrey D.
    Clark, Eva H.
    Marcus, Rachel
    Bern, Caryn
    EMERGING INFECTIOUS DISEASES, 2022, 28 (07) : 1313 - 1320
  • [29] Current Gaps and Needs for Increasing Access to Healthcare for People with Chagas Disease in the USA
    Forsyth, Colin J.
    Stigler Granados, Paula
    Pacheco, Gerardo J.
    Betancourt, Jose A.
    Meymandi, Sheba K.
    CURRENT TROPICAL MEDICINE REPORTS, 2019, 6 (01) : 13 - 22
  • [30] An update on benznidazole for the treatment of patients with Chagas disease
    Thakare, R.
    Dasgupta, A.
    Chopra, S.
    DRUGS OF TODAY, 2018, 54 (01) : 15 - 23